AUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback